Tafinlar (Dabrafenib)

Dabrafenib is a medicine used to treat melanoma and some other cancers that have a change in a gene called BRAF. It is taken as a capsule, or for children as a tablet mixed into liquid, usually together with a medicine called trametinib. It works by blocking the faulty BRAF protein that tells cancer cells to grow.

Brand names:Tafinlar
Medication

What people taking Tafinlar (Dabrafenib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Tafinlar (Dabrafenib) for Melanoma?

NameHow it went

About Tafinlar (Dabrafenib)

What It's For

Dabrafenib, sold as Tafinlar, is a targeted cancer medicine taken by mouth. It is used only for cancers whose cells carry a specific change in the BRAF gene, called a V600 mutation (most approvals require the V600E form; melanoma uses also cover the V600K form), which is confirmed by testing a sample of the tumor before treatment starts. In the US it is approved for melanoma (a skin cancer) that has spread or cannot be removed with surgery, and for up to a year after surgery to lower the chance of melanoma coming back once it has reached nearby lymph nodes. It is also approved for non-small cell lung cancer that has spread; anaplastic thyroid cancer, a rare and fast-growing thyroid cancer, when local treatments are not a good option; low-grade glioma, a slow-growing brain tumor, in children 1 year and older who need medicine treatment; and other advanced solid tumors with the V600E mutation, in adults and children 1 year and older, when earlier treatment has stopped working and there is no satisfactory alternative. That last approval is an accelerated approval: it rests on how often and how long tumors shrank, and further studies are needed to confirm the benefit. In nearly all of these uses, dabrafenib is taken together with trametinib (Mekinist), a second targeted medicine. Dabrafenib alone is approved only for advanced melanoma with the V600E form of the mutation. It is not used for colorectal cancer, where tumors resist this approach, or for tumors without a BRAF V600 mutation.

How It Works

BRAF is a protein that works like a switch in a chain of signals telling cells when to grow and divide. A V600 mutation leaves that switch stuck in the on position, so the cancer cell keeps receiving a signal to grow. Dabrafenib belongs to a group of drugs called kinase inhibitors. It attaches to the faulty BRAF protein and blocks it, which slows or stops the growth of cancer cells that depend on that signal. Trametinib blocks a different protein, called MEK, one step further along the same chain. Blocking two points at once gives stronger and longer-lasting control than blocking one, and in advanced melanoma studies the combination helped people live longer than a BRAF inhibitor on its own. In cells without the mutation, BRAF inhibitors can have the opposite effect and turn growth signals up, which is why the tumor test comes first.

Dosage & Administration

Dabrafenib comes as capsules and as tablets that are dissolved in water to make a liquid (tablets for oral suspension). Either form is taken twice a day, about 12 hours apart, on an empty stomach: at least 1 hour before or 2 hours after a meal. Adults usually take a standard dose, while children's doses are based on body weight and adjusted as they grow. Trametinib, when it is part of the plan, is taken once a day, so a written routine helps keep the two medicines straight. Capsules are swallowed whole and should not be opened, crushed or broken. The tablets for oral suspension are not swallowed, chewed or crushed. They are stirred into a small amount of water until dissolved, given right away by dosing cup, oral syringe or feeding tube, and thrown out if not used within 30 minutes. A baby or young child who cannot manage the fasting period can still breastfeed or have formula as needed. If a dose is missed, take it when remembered unless the next dose is less than 6 hours away; in that case, skip it. If vomiting happens after a dose, do not take an extra one. For advanced cancer, treatment usually continues as long as it keeps the cancer under control and side effects are manageable. After melanoma surgery, it is given for up to one year.

Side Effects

Fever is the side effect people most often notice, especially when dabrafenib is taken with trametinib, and it can come back in repeated episodes. It is sometimes accompanied by shaking chills, dehydration, dizziness from low blood pressure or kidney problems. Contact the care team right away about any fever during treatment. The care team will usually have you pause the medicines once temperature reaches 100.4°F or higher, and will tell you when, and at what dose, to restart. Other common effects with the combination include rash, dry skin, headache, joint and muscle aches, tiredness, nausea, vomiting, diarrhea, cough and swelling. Taken alone, dabrafenib also commonly causes thickened skin, small wart-like growths, hair thinning, and redness, swelling and pain on the palms and soles. Dabrafenib raises the chance of new skin cancers, mostly squamous cell and basal cell skin cancers and occasionally a new melanoma. This is more common when it is taken alone. Tell the care team promptly about a new wart, a sore or reddish bump that bleeds or will not heal, or a mole that changes in size or color. With trametinib, serious bleeding can occur, including rarely in the brain or digestive tract, and it has occasionally been fatal. Get medical help right away for signs of bleeding such as coughing up blood, vomiting blood or material that looks like coffee grounds, red or black tarry stools, or headaches with dizziness or weakness. The combination can also weaken the heart's pumping, so call the care team promptly about a pounding or racing heartbeat, new shortness of breath, swollen ankles or feet, or lightheadedness. Rarely, it can cause a severe skin reaction; call promptly about blistering or peeling skin, mouth sores or a rash with high fever. Whether dabrafenib is taken alone or with trametinib, it can cause inflammation inside the eye (uveitis), so call promptly about blurred or lost vision, eye pain or redness.

Interactions & Warnings

Dabrafenib can harm a developing baby. Women who could become pregnant have a pregnancy test before starting and need effective birth control during treatment. Because dabrafenib can make hormonal birth control such as pills, injections or patches unreliable, a non-hormonal method is recommended. Men with a partner who could become pregnant, including men who have had a vasectomy, should use condoms. Breastfeeding is not recommended during treatment. With dabrafenib alone, these precautions continue for 2 weeks after the last dose. When it is taken with trametinib, they continue for 4 months after the last trametinib dose. Dabrafenib may also reduce fertility in women and impair sperm production in men, possibly permanently, which is worth discussing before treatment if future children matter. Dabrafenib interacts with other medicines in both directions. Some medicines that slow the liver enzymes that break dabrafenib down, such as the antifungal ketoconazole and gemfibrozil (a medicine that lowers blood fats), can raise its levels and its side effects. In turn, dabrafenib speeds the breakdown of several other medicines and can make them less effective. Examples include hormonal birth control; dexamethasone, a steroid often used in cancer care; and warfarin, a blood thinner, which needs more frequent checks of the INR (international normalized ratio, a blood test of how quickly blood clots) when dabrafenib is started or stopped. Give the oncology team and pharmacist a full list of prescriptions, over-the-counter medicines and supplements. People with diabetes may find their blood sugar rises and their diabetes treatment needs adjusting; increased thirst or urinating more than usual is worth reporting. People with G6PD deficiency, an inherited enzyme shortage, can have red blood cells break down, so yellowing skin, weakness or breathlessness should be reported. Before starting, tell the care team about any bleeding problems, heart or eye conditions, and planned surgery or dental work.

What to Expect

Before treatment begins, the tumor is tested for the BRAF mutation. Other baseline checks usually include a skin exam, a pregnancy test where relevant and, when trametinib is part of the plan, a heart scan (an echocardiogram, which is an ultrasound of the heart, or a MUGA scan, a nuclear medicine scan of the heart) to measure how well the heart pumps. During treatment, skin exams continue about every 2 months and for up to 6 months after stopping, heart scans are repeated after the first month and then every 2 to 3 months, and blood tests and scans of the cancer follow the care team's schedule. Side effects such as fever are often handled by pausing the medicines briefly, lowering the dose or adding other treatment, rather than stopping for good. Repeat scans show whether the cancer is shrinking, holding steady or growing. In advanced cancer, treatment continues until the cancer starts growing again or side effects become too hard to manage, and the team then weighs other options. After melanoma surgery, a year of dabrafenib with trametinib clearly lowered the chance of the cancer returning compared with placebo in the main clinical trial.

Questions to Ask Your Doctor

  1. 1.Has my tumor been tested for a BRAF V600 mutation, and what did the result show?
  2. 2.Why do you recommend dabrafenib with trametinib for me rather than other options, such as immunotherapy?
  3. 3.What should I do if I get a fever, and who do I call after hours?
  4. 4.Which of my current medicines, including birth control, need to change while I take this?
  5. 5.How will we know it is working, and how often will I need skin checks, heart scans and other tests?

Last reviewed • Oct 2026

Educational content, not medical advice.